Janssen receives Complete Response Letter from FDA for sirukumab BLA
Janssen announced it has received a CRL from the FDA for the BLA seeking approval of sirukumab for treatment of moderately to severely active rheumatoid arthritis. The complete response letter indicates additional clinical data are needed to further evaluate the safety of sirukumab. September 22, 2017